# Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

> **NCT01287182** · PHASE3 · COMPLETED · sponsor: **Omicron Pharmaceuticals** · enrollment: 100 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Ateronon

## Key facts

- **NCT ID:** NCT01287182
- **Lead sponsor:** Omicron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2013-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01287182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01287182, "Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01287182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*